Daniel C. Cho

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso et al. · Cancer Discovery · 2013 · 699 citations

Pharmacy, Oncology, Pharmaceutics +17

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov et al. · The Lancet Oncology · 2018 · 368 citations

Medicine, Oncology, Pharmacology +10

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Nature Medicine · 2023 · 298 citations · Full text

Medicine, Oncology, Pharmacology +16

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel et al. · Cancer Discovery · 2020 · 238 citations · Full text

Pharmacy, Oncology, Pharmacology +17

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

Daniel C. Cho, Matthew B. Cohen, David J. Panka et al. · Clinical Cancer Research · 2010 · 191 citations · Full text

Medicine, Oncology, Pharmacology +17